Compare Biogen Inc (BIIB) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs KLA Corp. — how do they compare? Biogen Inc trades at $193.39 (market cap $28.34B), while KLA Corp. trades at $219.4 (market cap $300.93B). The key difference: KLA Corp. is far larger — about 10.6× Biogen Inc's market cap, and KLA Corp. pays a 0.4% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | KLAC | |
|---|---|---|
Market Cap | $28.34B | $300.93B |
Sector | Health | Technology |
52-Week High | $216.63 | $301.71 |
52-Week Low | $122.68 | $84.39 |
Enterprise Value | $30.62B | $302.11B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
KLA Corporation (KLAC) trades at $222.25, down 4.0% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock exhibits strong fundamentals with revenue growth to $12.16B in 2025 and net income of $4.06B, though valuation multiples remain elevated. Recent corporate actions include a 1:10 stock split effective June 12, 2026, and a $2.30 dividend paid in June 2026.
Outlook remains supported by AI-driven semiconductor equipment demand and consistent earnings beats, but rich valuation and competitive pressures pose risks. Analyst consensus is bullish with a $239.86 price target, suggesting potential upside from current levels if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
